November 21, 2026

EU regulators back Glaxo's OTC obesity treatment

European regulators have cleared the way for GlaxoSmithKline Plc to sell an over-the-counter version of Xenical, Roche Holding AG's prescription-only medicine for obesity.

bdnews24.com News Service

bdnews24.com

Published : 25 May 2007, 11:51 AM

Updated : 17 Aug 2022, 03:14 PM

LONDON, May 25 (bdnews24.com/Reuters) - European regulators have cleared the way for GlaxoSmithKline Plc to sell an over-the-counter version of Xenical, Roche Holding AG's prescription-only medicine for obesity. The European Medicines Agency said on Friday its experts had recommended granting marketing authorisation for Glaxo's version of orlistat -- the active ingredient in Xenical -- based the safety and efficacy of Roche's original product. Glaxo's low-dose non-prescription version of the drug was approved in February in the United States, where it is being launched under the brand name Alli. A launch in Europe, however, is not expected before 2008. Under the two-stage EU system, Glaxo still needs to file another dossier on its planned 60 mg dose of orlistat, having won a green light this week from experts for its initial submission based on 120 mg. A company spokesman said it hoped to file the 60 mg non-prescription formulation before the end of the year. Glaxo has no intention of selling a prescription strength version of the drug and rights to the prescription medication remain with Roche. The drug works by reducing the amount of fat the body absorbs from food and it is the only non-prescription weight-loss remedy with US Food and Drug Administration approval. Many companies sell over-the-counter supplements that claim weight-loss benefits, but those products are not cleared by the FDA. bdnews24.com/srs/1748 hrs
Related Stories